TickerTalks
Browse all tickers →
TickerTalks›$BIIB
BIBIIB

Biogen Inc.

$BIIB·$32B·Drug Manufacturers - General·Healthcare
$222.15-0.3%YTD+26.7%1Y+45.9%
Price updated 13h ago·X counts updated 4d ago
BIBIIB
$BIIBBiogen Inc.
$222.15-0.33%50 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $BIIB on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

50X posts · last 7 days
Sep 21Oct 4
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $BIIB's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 52% of tracked names.

Bullish sentimentAI analysisGenerated by AI from underlying data6 posts analyzed · as of 2026-09-09

The clean catalyst is LEQEMBI's subcutaneous formulation approved in China as an initiation treatment for early Alzheimer's — the first and only anti-amyloid therapy enabling at-home administration in that market. Political flow gets a mention (a Ways & Means Health member selling $BIIB along with the whole healthcare book), but nobody sees that as a real read on the drug.

Read what X is saying about $BIIB

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $BIIB — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Proven numbersEvent coming upAI verdict · as of 2026-10-03

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

Biogen at 89% of its range with LEQEMBI subcutaneous just approved in China — Oct 28 earnings validates the pipeline rebuild.

Biogen is the neuroscience pharma whose 2026 story has shifted from 'MS franchise erosion' to 'anti-amyloid and immunology pipeline validation.' The LEQEMBI subcutaneous approval in China plus the litifilimab Phase 2 lupus skin-symptom data are the specific recent operational signals.

  • The P&L is quietly working: Q2 revenue grew 1.9% YoY to $2.48B at a 16% operating margin and $2.17 EPS, with trailing EPS beats of 22.4% and 17% — these are large consistent surprises on a pharma whose Street models still assume MS-franchise decline is the dominant narrative.
  • The specific pipeline catalysts stack: LEQEMBI subcutaneous as first-and-only anti-amyloid at-home-administration therapy in China, litifilimab lupus Phase 2 data showing durable efficacy, and the experimental lupus skin-symptom data — three different pipeline readouts in the same quarter is unusually clean.

At 89% of its 52-week range going into Oct 28 earnings, the setup is late-cycle but supported. A clean LEQEMBI launch update plus any lupus-pipeline advancement is the trigger for continuation; a soft MS franchise revenue number or any LEQEMBI safety signal is the first warning.

Agrees with X sentimentThe LEQEMBI China subcutaneous approval and litifilimab Phase 2 data are specific grounded catalysts. The Ways & Means political-flow mention is noise.

What to watch: Oct 28 Q3 earnings — LEQEMBI launch metrics, MS franchise revenue, litifilimab pipeline commentary, and FY27 guide. LEQEMBI uptake plus litifilimab progress is the trigger; MS franchise erosion is the invalidation.

On the calendar: 2026-10-28 — Q3 earnings

event ahead 30dpipeline validation

Read the AI verdict on $BIIB

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Neuroscience-focused biotech commercializing treatments for multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - General sits in its cycle right now — and what that implies for $BIIB.

Drug Manufacturers - General · Healthcare

No material change from last week — GLP-1 duopoly (LLY/NVO) drives premium valuations while patent-cliff management defines the rest: ABBV migraine franchise win strengthens post-Humira portfolio.

What this means for $BIIB

Neutral — Neuroscience-focused biotech commercializing treatments for multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+15.7%YTD
+30.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
21.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
5.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
15.6%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
8.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
3.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
7.5%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
69.8%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.4Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 29, 2026$3.60$2.94+22.4%
Q1 2026Apr 29, 2026$3.57$3.05+17.0%
Q4 2025Feb 6, 2026$1.99$1.63+22.1%
Q3 2025Oct 30, 2025$4.81$3.88+24.0%
Next earningsWed, Oct 28·consensus EPS $2.04

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$2.5B+1.9%73.3%16.0%$2.17$696.7M
Q4 FY25$2.3B-7.1%78.2%-2.5%$-0.33$555.9M
Q3 FY25$2.5B-0.4%64.3%25.0%$3.18$1.2B
Q2 FY25$2.6B+7.3%64.2%22.2%$4.35$144.3M

Forward consensus

5-year forecast · up to 27 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$10.5B$10.1B – $10.6B$12.42$10.80 – $15.4124
FY27$10.7B$10.1B – $11.2B$16.55$11.60 – $19.8227
FY28$11.0B$10.1B – $11.6B$18.68$13.34 – $25.0326
FY29$11.2B$10.6B – $11.6B$20.51$19.07 – $21.4624
FY30$11.4B$10.8B – $11.8B$20.52$19.08 – $21.4714

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.3×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.91%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+2.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+13.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 146.4M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.9% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.175-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 4Lloyd MinorDirector593 sh$119KSellAug 3Lloyd MinorDirector593 sh$121K
+ 16 other (11 awards · 3 exempts · 2 inkinds) in window

See when $BIIB insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsAug 123
AI summary

Biogen (BIIB) filed a Form 3 initial statement of beneficial ownership for its Chief Legal Officer. The filing discloses the new insider's initial stock ownership positions. Specific share counts and security details are in the tabular section of the form.

8-KShareholder voteJun 108-K — Item 5.07: Shareholder vote
AI summary

Biogen held its 2026 Annual Meeting of Stockholders on June 9, 2026, with all ten director nominees elected for one-year terms through 2027. Most nominees received 100–121M 'for' votes, with Eric Rowinsky receiving the lowest support (~93.6M for) and Susan Langer the highest (~103.9M for). The meeting likely also addressed auditor ratification and compensation advisory votes, though those results are not shown in the excerpt. Standard governance event with no material impact.

SC 13D/AActivist amendmentMay 14SC 13D/A
AI summary

Biogen filed Amendment No. 1 to its Schedule 13D on Apellis Pharmaceuticals, Inc. as a final exit filing: Biogen now beneficially owns 0 shares (0.0%) of Apellis common stock, as all shares were irrevocably accepted for payment pursuant to the merger that closed May 14, 2026. This terminates Biogen's reporting obligation as a 5%+ holder of Apellis, which no longer exists as an independent public company following the acquisition. Procedural filing completing the Apellis/Biogen merger paper trail.

8-KAcquisition completedMay 148-K — Item 1.01: Material agreement · Item 2.01: Acquisition completed · Item 2.03: Material debt obligation · Item 7.01: Press release / Reg FD
AI summary

Biogen completed its acquisition of Apellis Pharmaceuticals on May 14, 2026, consummating the Agreement and Plan of Merger dated March 31, 2026. In connection with the merger, Biogen, Apellis, and Equiniti Trust Company entered into a Contingent Value Rights (CVR) Agreement governing CVRs issued to former Apellis shareholders; Biogen's subsidiary irrevocably accepted all Apellis shares tendered. The deal is transformative for Biogen's pipeline, adding Apellis's complement-targeting franchise (notably SYFOVRE/pegcetacoplan in geographic atrophy and other complement-mediated diseases) at a cost reflected in the ~$164M Q2 IPR&D charge disclosed separately.

+ 17 other (4 13Gs · 4 earnings 8-Ks · 3 SC TO-T/As · 2 10-Qs) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Stock Picks From Seeking Alpha's September 2026 New Analystsseekingalpha.com·1d agoBiogen expected to slightly beat third-quarter earnings as lupus trial data loom, Jefferies saysproactiveinvestors.com·2d agoWill Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?zacks.com·2d agoStoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndromegurufocus.com·3d agoBiogen's experimental lupus drug shows benefit against skin symptomsreuters.com·6d ago

More in Drug Manufacturers - General

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$LLY$NVO$PFE$MRK$JNJ$ABBV$OGN$BMY
Voices on X · last 7 days

No standout posts about $BIIB on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport